Trial of Cinpanemab in Early Parkinson’s Disease

Trial of Cinpanemab in Early Parkinson’s Disease

In a phase 2 trial in early Parkinson’s disease, treatment with cinpanemab, a monoclonal antibody to α-synuclein, did not affect clinical or imaging progression over a period of 72 weeks.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine 2022-08, Vol.387 (5), p.408-420
Hauptverfasser: Lang, Anthony E., Siderowf, Andrew D., Macklin, Eric A., Poewe, Werner, Brooks, David J., Fernandez, Hubert H., Rascol, Olivier, Giladi, Nir, Stocchi, Fabrizio, Tanner, Caroline M., Postuma, Ronald B., Simon, David K., Tolosa, Eduardo, Mollenhauer, Brit, Cedarbaum, Jesse M., Fraser, Kyle, Xiao, James, Evans, Karleyton C., Graham, Danielle L., Sapir, Inbal, Inra, Jennifer, Hutchison, R. Matthew, Yang, Minhua, Fox, Tara, Budd Haeberlein, Samantha, Dam, Tien
Format: Artikel
Sprache:eng
Schlagworte:
Aging
Aging General
Clinical trials
Cognitive ability
Computed tomography
Coronaviruses
COVID-19
Dopamine
Dopamine transporter
Geriatrics
Intravenous administration
Laboratories
Magnetic resonance imaging
Medical research
Monoclonal antibodies
Movement disorders
Neostriatum
Neurodegenerative diseases
Neurology
Neurosurgery
Parkinson Disease
Parkinson's disease
Pharmacokinetics
Placebos
Rhinopharyngitis
Single photon emission computed tomography
Synuclein
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:In a phase 2 trial in early Parkinson’s disease, treatment with cinpanemab, a monoclonal antibody to α-synuclein, did not affect clinical or imaging progression over a period of 72 weeks.
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMoa2203395